5 Stocks Insiders are Buying Now

In this article, we will look at the 5 stocks insiders are buying now. If you want to explore similar stocks, you can read 12 Stocks Insiders are Buying Now.

5. AMERCO (NASDAQ:UHAL)

Number of Hedge Fund Holders: 22

AMERCO (NASDAQ:UHAL) is an American do-it-yourself moving and storage operator for household and commercial goods. The company serves in the United States and Canada.

Insiders are piling into AMERCO (NASDAQ:UHAL). On December 9, the company reported in a regulatory filing that major shareholder Willow Grove Holdings Lp purchased 248,300 common shares of the company at $64.97 each. The transaction was valued at over $16 million.

At the end of the third quarter of 2022, 22 hedge funds disclosed positions in AMERCO (NASDAQ:UHAL). These funds held collective stakes of $745.3 million in the company. As of September 30, Yacktman Asset Management is the top stockholder in the company and has stakes of over $373.7 million.

4. Freshworks Inc. (NASDAQ:FRSH)

Number of Hedge Fund Holders: 27

Freshworks Inc. (NASDAQ:FRSH) is a leading global provider of cloud-based customer engagement and support solutions. On December 12, the company reported that director Sameer Gandhi acquired 590,000 common shares of Freshworks Inc. (NASDAQ:FRSH) at $14.85 per share for a total transaction amount of $8.76 million. Freshworks Inc. (NASDAQ:FRSH) is placed high among the stocks that insiders are buying right now.

On November 21, Credit Suisse analyst Rich Hilliker started coverage of Freshworks Inc. (NASDAQ:FRSH) with a Neutral rating and a $14 price target.

At the close of Q3 2022, 27 hedge funds were long Freshworks Inc. (NASDAQ:FRSH). These funds disclosed positions of $287.6 million, up from $177.4 million in the previous quarter with 25 positions. As of September 30, Tiger Global Management LLC is the dominant investor in the company and has a position worth 67.4 million.

3. Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY)

Number of Hedge Fund Holders: 28

Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) is a popular American restaurant and entertainment chain based in Dallas, Texas. At the close of the third quarter of 2022, 28 hedge funds were long Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) and held positions worth $453.3 million in the company. Of those, Hill Path Capital was the top shareholder in the company and held a position worth $155.7 million.

On December 8, Loop Capital analyst Alton Stump reiterated his $59 price target and a Buy rating on Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY).

On December 12, Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) disclosed in a regulatory filing that major shareholder Hill Path Capital purchased 287,961 common shares of the company at $34.66 each. The transaction was valued at $9.97 million. Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) is among the stocks that insiders are buying right now.

2. Harrow Health, Inc. (NASDAQ:HROW)

Number of Hedge Fund Holders: 13

Harrow Health, Inc. (NASDAQ:HROW) is a leading healthcare company with a dedicated focus on ophthalmic diseases. The company was founded in 1998 and is headquartered in Nashville, Tennessee. Insiders are racking up shares of Harrow Health, Inc. (NASDAQ:HROW). On December 14, the company disclosed in a regulatory filing that major shareholder Opaleye Management purchased 431,183 common shares at $10.52 per share. The transaction was valued at $4.53 million.

On October 3, Lake Street analyst Brooks O’Neil maintained a Buy rating and his $17 price target on Harrow Health, Inc. (NASDAQ:HROW).

At the close of the third quarter of 2022, 13 hedge funds were eager on Harrow Health, Inc. (NASDAQ:HROW) and held stakes of $87.1 million in the company. This is compared to 13 hedge funds in the previous quarter with stakes of $78.2 million.

Here is what SRK Capital had to say about Harrow Health, Inc. (NASDAQ:HROW) in its second-quarter 2022 investor letter:

“I have written about Harrow Health in my previous two letters to you, but I find it necessary to continue to explain my thought process in order to convey my conviction in the company. During periods of negative performance, I believe it is more vital than ever that our partners understand my thought process in order for you to adequately discern what it is that I do as your manager. HROW is our largest position, our largest detractor year to date, and the opportunity I am most excited about over the next six months.

Harrow Health is an ophthalmology focused healthcare company. The core business, ImprimisRx, is a compounding pharmacy that customizes medications to the needs of eye care physicians and their patients. It is estimated that north of 90% of ophthalmologists and optometrists use compounded formulations in their practice. Physicians choose to work with ImprimisRx because they are the largest and most trusted compounding pharmacy in the eye care market and have achieved this by solving pain points for physicians and their patients, where others could not satisfy their needs…” (Click here to see the full text)

1. Dyne Therapeutics, Inc. (NASDAQ:DYN)

Number of Hedge Fund Holders: 17

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a leading biotechnology company focused on developing breakthrough therapies for patients with serious genetic and degenerative muscle diseases. On November 29, JPMorgan analyst Tessa Romero updated her price target on Dyne Therapeutics, Inc. (NASDAQ:DYN) to $18 from $24 and maintained an Overweight rating on the shares.

On December 14, Dyne Therapeutics, Inc. (NASDAQ:DYN) reported that director Jason Rhodes acquired 934,581 shares of the company’s common stock at $10.70 per share. The transaction was valued at $10 million. Dyne Therapeutics, Inc. (NASDAQ:DYN) is a stock that insiders are piling into right now.

At the end of Q3 2022, 17 hedge funds were bullish on Dyne Therapeutics, Inc. (NASDAQ:DYN) and disclosed positions worth $163 million in the company. This is compared to 19 positions in the previous quarter worth $120.5 million. As of September 30, Deep Track Capital is the dominant investor in the company and has a position worth $40.4 million.

You can also take a look at 10 Stocks Most Affected By Inflation and 10 Biggest Dividend Cuts of 2022.